Financials
Financial year 2025
AUNERIPHARM from Brussel, company number BE1002796292, closed financial year 2025 with a result of € 92,126 after tax. For that financial year AUNERIPHARM recorded a gross margin of € 341,530 and equity of € 157,451. Compared with financial year 2024, the result moved from € 63,325 to € 92,126. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 8, 2026.
€ 157,451
▲ 141% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 92,126
▲ 45% vs 2024
Profit after tax over the fiscal year.
€ 208,061
▲ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 155,451.
People and assets in 2025
1.6
Average over the fiscal year, from the social balance sheet.
€ 210,485
▲ 59% vs 2024
€ 131,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 18,111
▲ 75% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 28,852
▲ 48% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 219,631 | € 341,530 | ▲ 56% |
| Profit after taxes | € 63,325 | € 92,126 | ▲ 45% |
| Equity | € 65,325 | € 157,451 | ▲ 141% |
| Total debts | € 179,869 | € 202,213 | ▲ 12% |
| Cash | € 202,864 | € 208,061 | ▲ 3% |
| Retained profit | € 63,325 | € 155,451 | ▲ 145% |
| Balance sheet total | € 245,194 | € 359,664 | ▲ 47% |
| Employees (FTE) | - | 1.6 |
Key figures of AUNERIPHARM, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AUNERIPHARM?
What happened at AUNERIPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 92,126 (▲ 45% vs 2024). Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
- ANTAURXEL SARL became a director. NBB
In short
From € 63,325 profit in 2024 to € 92,126 profit in 2025.
Paid € 56,578 in corporate taxes since 2024.
Best year ever: 2025, with € 92,126 profit.
On average € 213,500 of value added per employee in 2025.
A new publication or filing at AUNERIPHARM? We notify you, reason included.
Follow AUNERIPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Director · represented by Pastre Elodie
since 2023
Establishments
Establishment units
Physical locations of this company
Louizalaan 480
1050 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1002.796.292
- VAT number
- BE 1002.796.292
- Registered office
- Louizalaan 480, 1050 Brussel
- Names & denominations
- AUNERIPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 November 2023
- Peppol
- Active · Active since 3 Jul 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering